| INTRODUCTION
Ulcerative colitis affects one in 200-400 people in Western nations, and its global incidence and prevalence is rising. 1 While the majority of patients have a mild-moderate course, about 10%-15% patients experience severe disease course with significant morbidity with frequent flares and hospitalisations, requiring immunosuppressive therapies and corticosteroids, and impose a significant direct and indirect economic burden. 2, 3 Infliximab has conventionally been the mainstay of therapy for moderate-severe ulcerative colitis, and has been shown to modify the natural history of disease; however, approximately 1/3rd biologicna€ ıve patients have primary non-response to infliximab, and among those who respond, up to 45% lose response over time. 4, 5 Over the last 5 years, several newer biologics, including other anti-tumour necrosis factor-a (TNF) agents (adalimumab, golimumab) and anti-integrin agents (vedolizumab) have been approved by the United States food and drug administration (FDA) for management of moderate-severe ulcerative colitis; [6] [7] [8] additionally, recently an oral janus kinase inhibitor, tofacitinib, was shown to be effective in pivotal phase III trials. Hence, we conducted a systematic review with network metaanalyses, comparing the relative efficacy and safety of anti-TNF agents (infliximab, adalimumab, golimumab), anti-integrin agents (vedolizumab) and janus kinase inhibitors (tofacitinib) as first-and second-line agents in patients with moderate-severe ulcerative colitis. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for network meta-analysis to appraise the confidence in estimates. 11 
| ME TH ODS
This systematic review was performed using an a priori established protocol, and is reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) extension statement for systematic reviews incorporating network metaanalyses for health care interventions. 12 We followed good research practices outlined in the International society for pharmacoeconomics and outcomes research report on interpreting indirect treatment comparisons and network meta-analysis for healthcare decision-making. 13 
| Study selection
We conducted two separate pair wise and network meta-analyses of induction therapy to estimate comparative efficacy of different agents as first-(biologic-na€ ıve patients) and second-line agents (in patients with prior exposure to anti-TNFs) for management of moderate-severe ulcerative colitis. Studies included in these meta- For trials of maintenance therapy, the efficacy outcomes were maintenance of clinical remission and mucosal healing, and safety outcomes were serious adverse events (study-defined) and infections, which were analysed quantitatively. In addition, we qualitatively reviewed risk of any adverse events, adverse events resulting in treatment discontinuation, and risk of serious infections.
When data for multiple doses of the same medication were available, then for agents that have received regulatory approval, only data for approved dose and administration was considered; for agents that have not yet received regulatory approval, we used tofacitinib 10 mg b.d. for induction and 5 mg b.d. for maintenance.
Post-hoc sensitivity analysis using tofacitinib 10 mg b.d. dose for maintenance was performed. The timing of outcome assessment with induction trials was up to 14 weeks; when outcomes at multiple time points were reported, we used outcomes at week 8 or 6.
For maintenance trials, outcomes were assessed at last point of follow-up, usually week 52. The denominator used in all trials was based on intention-to-treat analysis, and all dropouts were assumed to be treatment failures for the primary outcome of clinical remission; for mucosal healing, only patients with follow-up endoscopy were included. For safety outcome, last-observation-carried-forward imputation was used.
| Data synthesis and statistical analysis
Pooled odds ratios (OR) and 95% confidence intervals (CI), were calculated using the Mantel-Haenszel fixed-effects model (in the absence of conceptual heterogeneity and if <5 studies), with sensitivity analysis using the DerSimonian-Liard random-effects model. [14] [15] [16] We assessed statistical heterogeneity using the I 2 statistic, with values over 50% suggesting substantial heterogeneity. Publication bias was assessed by evaluating small study effects by examining funnel plot asymmetry. 17 Direct comparisons were performed using RevMan v53 (Cochrane Collaboration, Copenhagen, Denmark). Next, we conducted network meta-analysis using a multivariate, consistency model, random-effects meta-regression as described by Ian White, using STATA v.13.0 (College Station, TX, USA). 18 This frequentist approach provides a point estimate from the network along with 95% CI from the frequency distribution of the estimate.
We calculated the relative ranking of agents for induction of clinical remission as their surface under the cumulative ranking (SUCRA), which represents the percentage of efficacy or safety achieved by an agent compared to an imaginary agent that is always the best without uncertainty (ie, SUCRA = 100%). 19 Higher SUCRA scores correspond to higher ranking for induction of clinical remission and/ or mucosal healing, and higher ranking for safety (ie, lowest risk of serious adverse events and infections).
Finally, we generated estimates of absolute event rates (or absolute risk) using the GRADEpro version 3.6 (McMaster University, 2014) (appendix S1). 20 
| Confidence in estimates
We followed the GRADE approach to appraise the confidence in estimates derived from network meta-analysis of efficacy outcomes. 11 In this approach, direct evidence from RCTs starts at high confidence and can be rated down based on risk of bias, indirectness, imprecision, inconsistency (or heterogeneity) and/or publication bias, to levels of moderate, low and very low confidence. The rating of indirect estimates starts at the lowest rating of the two pairwise estimates that contribute as first-order loops to the indirect estimate but can be rated down further for imprecision or intransitivity (dissimilarity between studies in terms of clinical or methodological characteristics). If direct and indirect estimates were similar (ie, coherent), then the higher of their rating can be assigned to the network meta-analysis estimates.
| RESULTS
From a total 1866 unique studies identified using our search strat- 25 ) and vedolizumab (GEMINI I 6 ) also reported outcomes on maintenance therapy, within the same publication; PURSUIT-M, PURSUIT-J and OCTAVE-SUSTAIN reported outcomes for maintenance therapy with for golimumab and tofacitinib respectively. 9, 26, 27 The schematic diagram of study selection is shown in Figure S1 and Trial and patient characteristics are summarised in 
Induction of clinical remission
On direct meta-analysis, all agents were superior to placebo for induction of clinical remission, and effect size was strongest for induction of clinical remission in biologic-na€ ıve patients (evidence rated down due to imprecision due to low event rate not meeting optimal information size) ( Table 2, Table S1 ). On comparison of active interventions, no head-to-head trials were identified. There T A B L E 2 Comparative efficacy of pharmacological agents for induction of clinical remission and mucosal healing in biologic-na€ ıve patients with moderate-severe ulcerative colitis, using network meta-analysis. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-defining and row-defining treatment. Bold numbers with darker background are statistically significant. For induction of clinical remission, odds ratio >1 favours row-defining treatment. For induction of mucosal healing, odds ratio >1 favours column-defining treatment. Numbers in parentheses indicate 95% confidence interval 
Tofacitinib

Induction of clinical remission
Induction of mucosal healing
On direct meta-analysis, all agents were superior to placebo for induction of mucosal healing, and effect size was strongest for infliximab (OR, 3.32) and vedolizumab (OR, 2.91) (Figure 4, Figure S4B) . On network meta-analysis, compared to placebo, high quality evidence supported the use of infliximab, adalimumab and golimumab, and moderate quality evidence supported the use of vedolizumab and tofacitinib for induction of mucosal healing in biologic-na€ ıve patients (evidence-rated down due to imprecision due to low event rate not meeting optimal information size for vedolizumab and tofacitinib) ( Table 2, Table S1 ). 24 one phase III trial of vedolizumab, 6 and subgroup analyses of two phase III trials of tofacitinib. 9 There were no trials of infliximab or, golimumab, in patients with prior exposure to anti-TNF, which met inclusion criteria. In trials of adalimumab, only patients with loss of response or intolerance to a prior anti-TNF agent were included. In contrast, in trials of vedolizumab, 48% patients had inadequate response to anti-TNF agents. These data were not available for tofacitinib.
Induction of clinical remission
On direct meta-analysis, tofacitinib, but not adalimumab or vedolizumab, was superior to placebo for induction of clinical remission ( Figure 5 , Figure S5A ). On network meta-analysis, compared to pla- 
Induction of mucosal healing
On direct meta-analysis, tofacitinib, but not vedolizumab or adalimumab, was superior to placebo for induction of mucosal healing ( Figure 6 , Figure S5B ). On network meta-analysis, compared to pla- Median rate of serious infections in induction trials with active intervention was 1.3% (interquartile range, 0.3-2.1).
| Comparative safety of induction therapy
| Maintenance therapy
| Efficacy
Due to differences in trial design, trials of infliximab and adalimimab (treat straight-through) and of golimumab, vedolizumab and tofacitinib (re-randomisation of responders to induction therapy) were analysed T A B L E 3 Comparative efficacy of pharmacological agents for induction of clinical remission and mucosal healing in patients with moderatesevere ulcerative colitis with prior exposure to anti-tumour necrosis factor-a (TNF) agents, using network meta-analysis. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-defining and row-defining treatment.
Bold numbers with darker background are statistically significant. (Table S4) . While the maintenance trial of golimumab was conducted in only anti-TNF-na€ ıve patients, trials of vedolizumab and tofacitinib included both anti-TNFna€ ıve and anti-TNF-exposed patients, but results were not stratified by prior anti-TNF exposure status. (Table S5 ).
| Comparative safety of maintenance therapy
| Publication bias
There was no evidence of small study effects on evaluation of funnel plot; however, the number of studies for each comparison was small, and we cannot reliably detect publication bias.
| DISCUSSION
In this systematic review and network meta-analysis, combining direct and indirect evidence from 14 trials including 4212 biologic-na€ ıve and -exposed patients with moderate-severe ulcerative colitis, we made several key observations. First, in biologic-na€ ıve patients, while all approved agents are effective, infliximab and vedolizumab are ranked 32, 33 In these analyses, data on how many prior anti-TNF agents to which a patient had been exposed was not consistently reported. It is conceivable that since anti-TNF agents were the first class of medications to be approved, patients treated with adalimumab or golimumab in clinical trials generally had exposure to only a single anti-TNF agent; in contrast, in subsequent trials of vedolizumab and tofacitinib, a significant proportion of patients may have been exposed to 2 or more biologic agents prior to clinical trial intervention, and may inherently be difficult to treat. We accounted for this observation in the GRADE schema by rating down comparisons of active interventions for intransitivity, and for imprecision, resulting in low or very low quality of evidence.
Besides inherent limitations of individual trials, there are limitations to our analyses. There were no head-to-head trials, and all comparative efficacy and safety analyses were based on indirect comparisons. A thorough comparative analysis across all agents was limited to trials of induction therapy; due to differences in trial design of maintenance therapy, we had conduct two separate network meta-analyses limiting comparative assessments. Approaches to conducting network meta-analyses when study designs are different have been proposed, but it is difficult to assess their validity. 34, 35 Most of the included trials relied on local investigators for endoscopic reading of endoscopic disease activity for trial recruitment and outcome assessment, whereas trials of tofacitinib included blinded central readers, which can influence absolute event rates of clinical remission and mucosal healing; additional the efficacy outcome in OCTAVE trials of tofacitinib were more robust, with requirement of a rectal bleeding subscore of 0. 36 There were subtle differences in timing of outcomes assessment in induction studies, and time-dependent variability in efficacy could not be analysed in detail. While corticosteroid-free remission may be a more relevant clinical endpoint, this was inconsistently reported in included trials.
Beyond treatment efficacy, safety is an integral part in determining risk-benefit balance of each intervention and informing shared decision-making. 37 While comparative analysis of maintenance trials suggested higher safety with vedolizumab, rates of important events like serious infections was low and other serious events like malignancy could not be thoroughly evaluated. Moreover, differences in study design of maintenance therapy (treat straight-through vs rerandomisation of responders) may potentially bias safety results by selective inclusion of patients who have demonstrated tolerability in the induction phases. Post-marketing surveillance studies of these different agents may better inform relative safety of these agents.
Integrating findings from this meta-analysis and other studies, 
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